Author

Nirja B. Patel

Observed name: Nirja Patel

Institution: Immunome (United States)

Observed institutions: Immunome (United States), Towson University

ORCID: 0000-0002-7946-3248

Observed ORCID: 0000-0002-7946-3248

OpenAlex ID: A5018479498

IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

2023 · John P. Dowling, Pavel A. Nikitin, et al. · mAbs · 18

IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

2022 · Pavel A. Nikitin, Jillian M. DiMuzio, et al. · Science Immunology · 13

Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein

2021 · Jillian M. DiMuzio, Baron C. Heimbach, et al. · Vaccine X · 9

823 IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy

2022 · John Dowling, Pavel Nikitin, et al. · Journal for ImmunoTherapy of Cancer

Abstract LBA022: IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo

2021 · John P Dowling, Pavel A Nikitin, et al. · Molecular Cancer Therapeutics

Evaluating the nuclease activity of Pseudomonas exotoxin A

2018 · Nirja Patel, Namo Jackson, et al. · The FASEB Journal

Refolding and Purification of Unmodified Human Elongation Factor 2 for the in vitro Reconstitution of Diphthamide Synthesis

2015 · Nirja Patel, Joshua Ostovitz, et al. · The FASEB Journal

Works count: 7

Citation count: 40

H-index: 3

I10-index: 2